Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB - Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Separately, HC Wainwright lowered their price objective on PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, March 27th.

PDS Biotechnology Price Performance

NASDAQ:PDSB traded down $0.15 during mid-day trading on Friday, reaching $1.43. 976,678 shares of the company were exchanged, compared to its average volume of 486,774. The stock has a market cap of $65.37 million, a PE ratio of -1.23 and a beta of 1.40. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.42. The company has a fifty day moving average of $1.23 and a 200 day moving average of $1.53.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, research analysts anticipate that PDS Biotechnology will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Iron Gate Global Advisors LLC purchased a new position in shares of PDS Biotechnology during the 1st quarter valued at about $89,000. Armistice Capital LLC bought a new position in shares of PDS Biotechnology during the 1st quarter valued at approximately $5,259,000. Blair William & Co. IL increased its position in shares of PDS Biotechnology by 63.3% during the 1st quarter. Blair William & Co. IL now owns 257,200 shares of the company's stock valued at $306,000 after purchasing an additional 99,700 shares during the last quarter. Two Sigma Investments LP grew its position in PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after acquiring an additional 48,132 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of PDS Biotechnology during the 4th quarter worth $58,000. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.